ArticleAnnals of surgical oncology2026
Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the Editor of Annals of Surgical Oncology Concerning "Financial Toxicity among Survivors of Extremity and Pelvic Sarcoma: A Retrospective Study".Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may lead to financial toxicity (FT), potentially impairing survivors' quality of life (QoL). We assessed FT from the perspective of CRS/HIPEC candidates and survivors, hypothesizing an association with QoL, and explored its dynamics and drivers. PATIENTS AND
methodsA cross-sectional, single-center study used in-person Comprehensive Score for Financial Toxicity (COST) (FT) and Functional Assessment of Cancer Therapy-General (FACT-G) (QoL) surveys among CRS/HIPEC candidates/survivors with various primary tumors up to 5 years postoperatively. Spearman correlation between COST and FACT-G was assessed. Risk factors for FT were identified using a generalized linear model with forward selection among clinical, sociodemographic, and financial variables, as well as time from CRS/HIPEC.
resultsOverall, 248 surveys were analyzed: 55 (22.2%) candidates and 193 (77.8%) survivors. Mean ± standard deviation (SD) age was 59 ± 11 years, and 75% were female individuals. Appendix cancer was the most prevalent (42.3%), followed by ovarian (33.9%), colon (14.5%), and other (9.3%). The mean ± SD COST score was 29.7 ± 10.7 (range: 0-44), with 31.0% experiencing moderate-to-severe FT (COST ≤ 25). COST and FACT-G scores were strongly correlated (rho = 0.51, p < 0.001). Risk factors for greater FT (p < 0.05) included preoperative (β = -3.7) and adjuvant chemotherapy (β = -3.2), identifying as Black, Indigenous, or person of color (β = -5.4), being single (β = -3.5), and higher co-pays within 90 days before/after CRS/HIPEC (β range: -3.0 to -3.9). FT decreased over time (p = 0.008), reaching its lowest levels by 1 year postoperatively.
conclusionsFT is strongly associated with poorer QoL among CRS/HIPEC candidates/survivors. Risk factors include perioperative chemotherapy, higher co-pays from perioperative care, and sociodemographic disadvantages. Financial well-being improves by 1 year post-CRS/HIPEC.
Indexed as
Identifiers
41772250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.